Antihyperalgesic activity of a mexicanolide isolated from Swietenia humilis extract in nicotinamide-streptozotocin hyperglycemic mice

Berenice Ovalle-Magallanes, Myrna Déciga-Campos, Rachel Mata

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

© 2017 Swietenia humilis Zucc. (Meliaceae) seeds are used in Mexico for the treatment of type 2 diabetes mellitus. Mexicanolides are the main hypoglycemic and antihyperglycemic compounds of the species. This study was conducted to investigate the antihyperalgesic effect of an aqueous extract of the seeds of Swietenia humilis (SHAE) and of mexicanolide 2-hydroxy-destigloyl-6-deoxyswietenine acetate (1), using the formalin test in mice. The antihyperalgesic actions of SHAE and mexicanolide 1, as well as its possible transductional activity, were assessed in nicotinamide-streptozotocin (NA-STZ) hyperglycemic mice. Local injection of SHAE (10–177 μg) and mexicanolide 1 (0.5–3.5 μg) exhibited concentration-dependent antihyperalgesic action in NA-STZ hyperglycemic mice. Ketanserin (6 μg), a 5-HT2A/C receptor antagonist, and flumazenil (6 μg), a GABAA receptor antagonist, abolished the antihyperalgesic effect of mexicanolide 1 (3 μg). On the other hand, naloxone (3 μg), L-arginine (50 μg), and Nω-Nitro-L-arginine methyl ester hydrochloride (150 μg) diminished the antihyperalgesic effect of mexicanolide 1. The aqueous extract of the seeds possesses significant antihyperalgesic action. Compound 1 produces antihyperalgesia through GABAA, 5-HT2A/C and opioid receptors. Also, the nitrergic system is involve in the antihyperalgesic effect of 1. Data obtained with Swietenia humilis Zucc. seeds give evidence of its potential for pain associated with diabetes treatment.
Original languageAmerican English
Pages (from-to)324-330
Number of pages290
JournalBiomedicine and Pharmacotherapy
DOIs
StatePublished - 1 Aug 2017

Fingerprint

Meliaceae
Obese Mice
Niacinamide
Streptozocin
Seeds
Receptor, Serotonin, 5-HT2A
Hypoglycemic Agents
Arginine
GABA-A Receptor Antagonists
Flumazenil
Ketanserin
Opioid Receptors
Pain Measurement
Naloxone
Mexico
Type 2 Diabetes Mellitus
Acetates
mexicanolide
Pain
Injections

Cite this

@article{a6b7c489374142f984f05525277c988d,
title = "Antihyperalgesic activity of a mexicanolide isolated from Swietenia humilis extract in nicotinamide-streptozotocin hyperglycemic mice",
abstract = "{\circledC} 2017 Swietenia humilis Zucc. (Meliaceae) seeds are used in Mexico for the treatment of type 2 diabetes mellitus. Mexicanolides are the main hypoglycemic and antihyperglycemic compounds of the species. This study was conducted to investigate the antihyperalgesic effect of an aqueous extract of the seeds of Swietenia humilis (SHAE) and of mexicanolide 2-hydroxy-destigloyl-6-deoxyswietenine acetate (1), using the formalin test in mice. The antihyperalgesic actions of SHAE and mexicanolide 1, as well as its possible transductional activity, were assessed in nicotinamide-streptozotocin (NA-STZ) hyperglycemic mice. Local injection of SHAE (10–177 μg) and mexicanolide 1 (0.5–3.5 μg) exhibited concentration-dependent antihyperalgesic action in NA-STZ hyperglycemic mice. Ketanserin (6 μg), a 5-HT2A/C receptor antagonist, and flumazenil (6 μg), a GABAA receptor antagonist, abolished the antihyperalgesic effect of mexicanolide 1 (3 μg). On the other hand, naloxone (3 μg), L-arginine (50 μg), and Nω-Nitro-L-arginine methyl ester hydrochloride (150 μg) diminished the antihyperalgesic effect of mexicanolide 1. The aqueous extract of the seeds possesses significant antihyperalgesic action. Compound 1 produces antihyperalgesia through GABAA, 5-HT2A/C and opioid receptors. Also, the nitrergic system is involve in the antihyperalgesic effect of 1. Data obtained with Swietenia humilis Zucc. seeds give evidence of its potential for pain associated with diabetes treatment.",
author = "Berenice Ovalle-Magallanes and Myrna D{\'e}ciga-Campos and Rachel Mata",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.biopha.2017.05.073",
language = "American English",
pages = "324--330",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",

}

Antihyperalgesic activity of a mexicanolide isolated from Swietenia humilis extract in nicotinamide-streptozotocin hyperglycemic mice. / Ovalle-Magallanes, Berenice; Déciga-Campos, Myrna; Mata, Rachel.

In: Biomedicine and Pharmacotherapy, 01.08.2017, p. 324-330.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antihyperalgesic activity of a mexicanolide isolated from Swietenia humilis extract in nicotinamide-streptozotocin hyperglycemic mice

AU - Ovalle-Magallanes, Berenice

AU - Déciga-Campos, Myrna

AU - Mata, Rachel

PY - 2017/8/1

Y1 - 2017/8/1

N2 - © 2017 Swietenia humilis Zucc. (Meliaceae) seeds are used in Mexico for the treatment of type 2 diabetes mellitus. Mexicanolides are the main hypoglycemic and antihyperglycemic compounds of the species. This study was conducted to investigate the antihyperalgesic effect of an aqueous extract of the seeds of Swietenia humilis (SHAE) and of mexicanolide 2-hydroxy-destigloyl-6-deoxyswietenine acetate (1), using the formalin test in mice. The antihyperalgesic actions of SHAE and mexicanolide 1, as well as its possible transductional activity, were assessed in nicotinamide-streptozotocin (NA-STZ) hyperglycemic mice. Local injection of SHAE (10–177 μg) and mexicanolide 1 (0.5–3.5 μg) exhibited concentration-dependent antihyperalgesic action in NA-STZ hyperglycemic mice. Ketanserin (6 μg), a 5-HT2A/C receptor antagonist, and flumazenil (6 μg), a GABAA receptor antagonist, abolished the antihyperalgesic effect of mexicanolide 1 (3 μg). On the other hand, naloxone (3 μg), L-arginine (50 μg), and Nω-Nitro-L-arginine methyl ester hydrochloride (150 μg) diminished the antihyperalgesic effect of mexicanolide 1. The aqueous extract of the seeds possesses significant antihyperalgesic action. Compound 1 produces antihyperalgesia through GABAA, 5-HT2A/C and opioid receptors. Also, the nitrergic system is involve in the antihyperalgesic effect of 1. Data obtained with Swietenia humilis Zucc. seeds give evidence of its potential for pain associated with diabetes treatment.

AB - © 2017 Swietenia humilis Zucc. (Meliaceae) seeds are used in Mexico for the treatment of type 2 diabetes mellitus. Mexicanolides are the main hypoglycemic and antihyperglycemic compounds of the species. This study was conducted to investigate the antihyperalgesic effect of an aqueous extract of the seeds of Swietenia humilis (SHAE) and of mexicanolide 2-hydroxy-destigloyl-6-deoxyswietenine acetate (1), using the formalin test in mice. The antihyperalgesic actions of SHAE and mexicanolide 1, as well as its possible transductional activity, were assessed in nicotinamide-streptozotocin (NA-STZ) hyperglycemic mice. Local injection of SHAE (10–177 μg) and mexicanolide 1 (0.5–3.5 μg) exhibited concentration-dependent antihyperalgesic action in NA-STZ hyperglycemic mice. Ketanserin (6 μg), a 5-HT2A/C receptor antagonist, and flumazenil (6 μg), a GABAA receptor antagonist, abolished the antihyperalgesic effect of mexicanolide 1 (3 μg). On the other hand, naloxone (3 μg), L-arginine (50 μg), and Nω-Nitro-L-arginine methyl ester hydrochloride (150 μg) diminished the antihyperalgesic effect of mexicanolide 1. The aqueous extract of the seeds possesses significant antihyperalgesic action. Compound 1 produces antihyperalgesia through GABAA, 5-HT2A/C and opioid receptors. Also, the nitrergic system is involve in the antihyperalgesic effect of 1. Data obtained with Swietenia humilis Zucc. seeds give evidence of its potential for pain associated with diabetes treatment.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85019953543&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85019953543&origin=inward

U2 - 10.1016/j.biopha.2017.05.073

DO - 10.1016/j.biopha.2017.05.073

M3 - Article

C2 - 28551554

SP - 324

EP - 330

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -